Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...

Activist investor Starboard Value may not be able to do much to help Pfizer Inc. (NYSE:PFE), according to a Wells Fargo ...

Tata Motors' British luxury car unit, Jaguar Land Rover (JLR), reported a three percent decline in retail sales to 1,03,108 ...

GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...

Although not all bats carry rabies, the city's health department wants people to seek post-exposure prophylaxis if they were bitten, scratched, or had contact with a bat. Meanwhile, travelers from ...

GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a ...

GSK has announced positive results from a phase III trial of its Arexvy RSV vaccine, showing that just one dose of the treatment could help protect older adults at risk of RSV disease over three ...

Arexvy is the world's first approved RSV vaccine and results showed that after a single dose, cumulative efficacy over three full RSV seasons was clinically meaningful.

GSK said data from a late-phase study showed that its respiratory syncytial virus vaccine, Arexvy, granted protection over three full RSV seasons.

GSK's Arexvy RSV vaccine demonstrated 43.3% effectiveness in preventing severe illness in its third trial season, following 94.1% effectiveness initially and 64.2% in the second year. The vaccine, one ...